Oxytocin
OXT
Endogenous bonding nonapeptide; large autism trial (SOARS-B) found no benefit over placebo
Overview
Oxytocin is an endogenous cyclic nonapeptide synthesized in the hypothalamus and released from the posterior pituitary. Its injectable form is one of the oldest peptide medicines, used intravenously or intramuscularly in obstetrics to induce labor and control postpartum bleeding through its action on uterine oxytocin receptors. In that setting it is given under continuous monitoring because of risks such as uterine hyperstimulation and water intoxication.
Beyond obstetrics, oxytocin is studied — almost always intranasally — for its role in social bonding, trust, empathy, and sexual and relational behavior. Intranasal delivery is the standard research route precisely because the peptide does not meaningfully cross the blood-brain barrier from the bloodstream; even so, intranasal central bioavailability is low (on the order of 1–2%), and a central half-life of roughly 20 minutes means effects are typically measured within a 30–90 minute window after dosing. Some community protocols also use subcutaneous oxytocin, but high peripheral plasma spikes from that route do not reliably translate into central effects.
The behavioral evidence is genuinely mixed. The largest and most rigorous trial, SOARS-B (Sikich et al., NEJM 2021), randomized 290 children and adolescents with autism to intranasal oxytocin or placebo over 24 weeks and found no significant difference on social or behavioral endpoints — a notable setback for the strongest version of the 'social peptide' hypothesis. Smaller studies report effects on trust, pair-bonding, and sexual response, but reproducibility is inconsistent. The figures below reflect this state of the evidence and are provided for research reference only.
Key parameters
- Dose range
- 24 IU intranasal (research); 0.5–1 mU/min IV (obstetric label)
- Frequency
- Per session (intranasal) or continuous infusion (obstetric)
- Half-life
- Plasma ~3–6 min; central ~20 min after intranasal
- Route
- Intranasal (research); intravenous/intramuscular (approved obstetric)
- Vial sizes
- —
- Regulatory status
- The injectable form is a long-approved obstetric medicine (labor induction, postpartum hemorrhage) given intravenously/intramuscularly under monitoring. Intranasal and subcutaneous use for social, behavioral, or sexual purposes is off-label/research; research-vial material is laboratory use only.
Mechanism of action
Oxytocin receptor (OXTR) agonism
Binds the G-protein-coupled oxytocin receptor on uterine and mammary smooth muscle (the basis of its obstetric use) and on central neurons. The receptor can couple to both excitatory (Gq) and inhibitory (Gi) pathways, which is one reason its dose-response can be non-linear.
Central social / affiliative signaling
Central OXTR activity in limbic and reward circuits is studied for effects on bonding, trust, empathy, and sexual/relational behavior. The magnitude and reliability of these intranasal effects are debated given low central bioavailability and mixed trial results.
Dosing protocol & phases
| Phase | Weeks | Dose | Notes |
|---|---|---|---|
| Intranasal (research) | Per session | 24 IU single dose (dose-ranging studies used 9, 18, or 36 IU) | The most common social-cognition research dose; autism trials used up to 48 IU/day split twice daily. |
| Subcutaneous (community) | Ongoing | 100–500 mcg once daily | Community range; peripheral plasma rises sharply but central effects are unreliable by this route. |
| Intravenous (approved obstetric) | Hospital use only | Begin ~0.5–1 milliunit/min, titrated under monitoring | The only approved indication; administered by clinicians, not a self-dosed protocol. |
Supplies needed
Affiliate disclosure: we may earn a commission from supplier links, at no extra cost to you. For research and educational use only.
Recommended supply
Oxytocin — research vial
From our verified partner Dynotides, with a third-party certificate of analysis per batch.
Injection supplies
- View
Bacteriostatic water
Diluent for reconstituting lyophilized vials.
- Buy
Insulin syringes (U-100)
0.3–0.5 mL, 29–31 G for accurate small draws.
- Buy
Alcohol prep pads
Sterile swabs for the vial stopper and site.
- Buy
Sharps container
Safe disposal of used needles.
- Buy
Storage fridge
Keeps reconstituted vials at 2–8 °C.
- Buy
Insulated travel case
Cooled, TSA-friendly case for travel.
Missed-dose guidance
Intranasal and subcutaneous use are off-label and typically taken on a per-session or daily basis, so a missed dose is simply skipped — given the few-minute plasma half-life there is no benefit to doubling up. Approved obstetric infusions are titrated in real time by clinicians and do not involve patient-managed missed doses.
Side effects & safety
| Category | Effect | Trial incidence |
|---|---|---|
| Respiratory (intranasal) | Nasal irritation, sneezing, runny noseMost common with the intranasal route; generally mild. | — |
| Neurological | Transient headache or fatigue | — |
| Psychiatric | Irritability or mood changesOccasionally reported, more so at higher doses. | — |
| Injection site (subcutaneous) | Redness, bruising, soreness | — |
| Obstetric (IV label) | Uterine hyperstimulation, water intoxication, arrhythmiasSerious risks specific to high-dose obstetric infusion under monitoring — distinct from low-dose research use. | — |
Clinical trials & evidence
SOARS-B (intranasal oxytocin in autism)
Phase 2 (RCT)24 weeks · 290 children/adolescents with autism spectrum disorder
No significant difference between intranasal oxytocin and placebo on primary or secondary social/behavioral endpoints — the largest, most rigorous test of the social-peptide hypothesis to date.
NCT01944046 ↗Intranasal oxytocin social-cognition studies
Phase 1/2 (research)Single-session / short-term · Adults in mechanistic and behavioral studies
Smaller studies report effects on trust, bonding, and sexual/relational measures (commonly at 24 IU), but reproducibility across labs is inconsistent.
Trial identifier needs verification
Storage & handling
- Lyophilized
- Store lyophilized research powder frozen at −20 °C, protected from light. Commercial liquid obstetric formulations follow their own labeling and refrigeration requirements.
- Reconstituted
- Refrigerate reconstituted/compounded solution at 2–8 °C and use within ~2–4 weeks. Do not freeze the reconstituted solution; avoid repeated freeze-thaw cycles.
Comparisons
| Vs. | Target | Half-life | Dosing | Efficacy | Status |
|---|---|---|---|---|---|
| PT-141 (Bremelanotide) | Oxytocin receptor (bonding) vs melanocortin MC4R (desire) | Minutes vs ~2.7 h | 24 IU intranasal vs 1.75 mg subcutaneous | Mixed/off-label for behavior vs approved for HSDD | IV-approved (obstetrics), off-label otherwise vs FDA-approved (Vyleesi) |
| Kisspeptin | Oxytocin receptor vs KISS1R (reproductive axis) | Minutes vs minutes | Mostly intranasal vs subcutaneous/IV | Social/affiliative (mixed) vs sexual brain processing (investigational) | IV-approved (obstetrics) vs investigational |
Sources & references
Frequently asked questions
Is oxytocin an approved drug?
Its injectable (intravenous/intramuscular) form is a long-approved obstetric medicine for labor induction and postpartum bleeding. The intranasal and subcutaneous uses related to bonding, mood, and sexual behavior are off-label/research.
Why is oxytocin given intranasally for behavioral research?
Oxytocin does not meaningfully cross the blood-brain barrier from the bloodstream, so the intranasal route is used in an attempt to reach the brain directly. Central bioavailability is still low (roughly 1–2%), which is part of why behavioral results are inconsistent.
Does the science support oxytocin for social or sexual benefit?
The evidence is mixed. Some small studies show effects on trust and bonding, but the largest rigorous trial (SOARS-B in autism) found no benefit over placebo. It should be viewed as an active research area rather than an established treatment.
Related protocols
PT-141 (Bremelanotide)
Bremelanotide
FDA-approved (2019) for premenopausal hypoactive sexual desire disorder
Kisspeptin
Kisspeptin-10
+56% penile rigidity vs placebo in men with HSDD (Comninos/Dhillo, 2023)
Looking to match this protocol to a verified research vial? Our partner supplier publishes a certificate of analysis per batch.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.